


## Utilizing New Technology In The Management Of Ocular Disease

Michael Cymbor, OD

The following presentation is part of the Woo U educational initiative. The presenter is supplying the information provided herein. Woo U takes no responsibility for the accuracy of the information, comments, or opinions expressed by the presenter(s). Any reproduction, in whole or in part, of any assets, including but not limited to images, videos, audio, data, research, descriptions, or accounts of the lecture, without the presenter's written consent is prohibited.



1



# WELCOME!




Host: Dr. Jennifer Stewart





2

## Thank you to Visionix for exhibiting at this event.




3

- For each hour of CE units, attendees ***must be online for a minimum of 50 minutes***
- For a COPE certificate, please fill out the survey link in the chat. Also, the survey link will appear when the webinar ends.
- CE certificates will be delivered by email and sent to ARBO with OE tracker numbers
- We will also display a QR code at the end of the event if you have the OE tracker app on your phone.
- ***CE certificates will be emailed within 4 weeks***
- Ask questions using the zoom on-screen floating panel





4



5

## All financial relationships have been mitigated.



6

### Speaker Bio –



Dr. Cymbor joined Nittany Eye Associates in 1997. He received his optometric doctorate from the Pennsylvania College of Optometry. He completed a residency in hospital-based optometry with an emphasis in ocular disease at the Wilkes-Barre VA Medical Center.

Dr. Cymbor was named Pennsylvania's "Young Optometrist of the year" in 2000. He was awarded the "Young Optometrist of the Year" by the American Optometric Association in 2001. He was also named as one of the top 175 optometrists in the nation by Newsweek.

He is a Primary Care Optometry News top 250 optometrist. He was a co-winner of the Best of State College in 2021, and named "Best Optometrist of State College" in 2022.

He is a principal investigator in numerous research studies in contact lenses, glaucoma and dry eye. He is published in Optometry and Vision Science, Review of Optometry, Optometry, Primary Care Optometry News, Advanced Ocular Care, Optometric Management, Review of Optometric Business, New OD, and Optometry Times. He was a guest on the "Ask the Eye Doctor" State College radio show.

He is a fellow of the American Academy of Optometry. He is a member of the Optometric Glaucoma Society, the National Optometric Society, the American Optometric Association, the Pennsylvania Optometric Association, and Mid-Counties Optometric Society.

Dr. Cymbor is an adjunct clinical professor at the Pennsylvania College of Optometry (PCO). He is also the co-founder of both the Glaucoma Institute of State College and the Dry Eye Institute of State College. He's also been the Opening Eyes clinic director of the Pennsylvania Special Olympics Summer State Games for over twenty years.

**WOO UNIVERSITY**

7


### Financial Disclosures

I am a speaker/KOL for the following:

- Visionix (Optovue)
- Quidel
- New World Medical
- LKC Technologies
- Allergan
- Tarsus
- Sight Sciences
- Thea Pharmaceuticals

**WOO UNIVERSITY**

8



9

### NIH News Release

#### Visual impairment, blindness cases in U.S. expected to double by 2050

*NIH-funded studies tease out trends by race, ethnicity and sex.*

[Facebook](#) [Twitter](#) [LinkedIn](#) [YouTube](#)

With the youngest of the baby boomers hitting 65 by 2025, the number of people with visual impairment or blindness in the United States is expected to double to more than 8 million by 2050, according to projections based on the most recent census data and from studies funded by the National Eye Institute, part of the National Institutes of Health. Another 16.4 million Americans are expected to have difficulty seeing due to correctable refractive errors such as myopia (nearsightedness) or hyperopia (farsightedness) that can be fixed with glasses, contacts or surgery.

The researchers were led by Rohit Varma, M.D., director of the University of



10

### Increased Demand for Medical Eye Care

- 20 million more routine and medical eye exams will be required in 2025 than were needed in 2015, and this number will continue to increase every year for the foreseeable future
- The number of FTE optometrists will increase by 13% between 2015 and 2025
- The number of FTE ophthalmologists will increase by 2.1% between 2015 and 2025


"The future of Optometry in America", Richard Edlow, OD. Modern Optometry March 2019

11


### Imbalance of supply/demand




12




13




14




15



16



17



18



19

### Three Ocular Disease States


	Glaucoma	Diabetic Retinopathy	AMD
Structure	Photos/OCT	Photos/OCT	Photos/OCT
Function	Visual Fields	?	?
Early Diagnosis	ERG/OCT-A	ERG/OCT-A	Dark Adaptation/OCT-A (wet)

20

### Diabetic Retinopathy

Structure	Photos/OCT	
Function	?	
Early Diagnosis	ERG/OCT-A	

21



22

### How does OCTA work?

OCTA uses motion contrast to detect flow from OCT data

Difference of two B-scans:

Flow signal (Red) Overlay on OCT B-scan

23


### Diabetic Retinopathy

- **Positive Indicators**
  - ❖ Retinal capillary non-perfusion seen as blackened area without blood flow outside FAZ
  - ❖ Microaneurysms
  - ❖ Enlarged FAZ


Control

24







25




26




27




28




29



30




31




32



33



34



35



36

ERG is an effective screening device at all levels of DR

• Zeng Y, Cao D, Yang D, Zhuang X, Yu H, Hu Y, Zhang Y, Yang C, He M, Zhang L. Screening for diabetic retinopathy in diabetic patients with a mydriasis-free, full-field flicker electroretinogram recording device. Documenta Ophthalmologica. 2019 Nov 12:1-0.

37

### Pupil responses become attenuated as diabetic retinopathy gets worse

- 1992 Smith & Smith; Straub, Jeron, & Kerp
- 1994 Straub, Thies, Jeron, Palitzsch, & Scholmerich
- 2001 Nakayama et al.
- 2013 Ortube et al.
- 2016 Maa et al.
- 2020 Brigell et al.

38

<b>DR Score</b>	22.1
Operator selected limits (7.5 - 23.4)	Within limits
95% Reference interval (7.4 - 25.1)	99%

39

## Structure and Function

Is a much more powerful predictor than structure alone

40

41

### Retinal Ganglion Cells

- There is a growing body of evidence suggesting that, prior to irreversible cell death, compromised retinal ganglion cells (RGCs) enter a dysfunctional state that may partially recover under certain conditions

42







**“Almost all published articles demonstrated a significant reduction of blood flow, capillary diameter and vascular density in glaucomatous eyes. Interestingly, these differences were detectable even in glaucoma suspects and eyes with preperimetric glaucoma and increased proportional to the severity of glaucoma damage.”**

Investigator	Year of publication	Main findings
Sub MEI, et al <sup>20</sup>	2016	Peripapillary microvascular density was much lower ( $P < .01$ ) of 57 POAG eyes. This finding was associated with higher structural damage, defects in lamellae thickness, reduced superficial vessel density in RNFL, thinner choroid and lower choroidal blood pressure.
Noji H, et al <sup>21</sup>	2016	Peripapillary vessel density was significantly lower ( $P < .001$ ) in 41 glaucoma eyes without such a defect. This difference was significant after adjusting for disease severity.
Yamashiro M, et al <sup>22</sup>	2016	Microvascular density was lower in 41 POAG eyes compared to 31 normal eyes. Macular capillary density correlated with mean retinal thickness and severity of visual field damage.
Yamashiro M, et al <sup>23</sup>	2016	In a cohort of 31 healthy subjects, 46 glaucoma suspects and 74 glaucoma patients, microvascular network in peripapillary RNFL was different in normal eyes compared to glaucoma suspects and glaucoma patients. The vascular density significantly correlated with visual field loss and this association was stronger than that of RNFL or macular thickness.
Chikara E, et al <sup>24</sup>	2017	Peripapillary and whole image vascular density measured by OCTA had similar diagnostic accuracy to peripapillary RNFL thickness measurement for detection of glaucoma eyes in a sample of 261 eyes. Peripapillary vessel density and peripapillary thickness were significantly lower in 41 POAG eyes than in 25 normal eyes.
Lee HJ, et al <sup>25</sup>	2017	Peripapillary capillary density was significantly lower in affected eyes of 11 unilateral NCG patients compared to unaffected eyes of the same patients and 11 eyes of healthy subjects. Reduced capillary network was compromised in the area corresponding to RNFL defect. In these cases, choroidal and CNV thickness did not show apparent change.
Kwon J, et al <sup>26</sup>	2017	FAZ irregularity demonstrated a significant association with presence of central visual field loss in 76 POAG patients with central or peripheral visual field damage and FAZ area was correlated with the severity of central field loss. The FAZ area was a significant predictor for visual field loss.

Abb. Disc. flow index; FAZ, foveal avascular zone; CCG, ganglion cell complex; NCG, normal tension glaucoma; CNV, optic nerve head; OCT, optical coherence tomography; POAG, primary open-angle glaucoma; RNFL, retinal nerve fiber layer; RNFL, retinal nerve fiber layer; VFL, visual field index.

• Daneshvar R, Nouri-Mahdavi K. Optical Coherence Tomography Angiography: A New Tool in Glaucoma Diagnostics and Research. *J Ophthalmic Vis Res.* 2017;12(3):325-332. doi:10.4103/jovr.jovr\_36\_17

49

## OCT-A in Glaucoma

- “OCTA enhanced both the sensitivity and specificity for glaucoma diagnosis.”
- “OCTA could accurately detect glaucomatous eyes, which may be misdiagnosed by OCT as normal, and OCTA could detect normal eyes, which may be misdiagnosed by OCT as glaucomatous.”
- “Therefore, these two modalities complemented each other in the diagnosis of glaucoma.”

Kwon HJ, Kwon J, Sung KR. Additive Role of Optical Coherence Tomography Angiography Vessel Density Measurements in Glaucoma Diagnoses. *Korean J Ophthalmol.* 2019;33(4):315-325


50

## OCT-A

- Eyes underwent IOP-lowering glaucoma surgery and their fellow (non-surgical) eyes were included.
- OCTA of the macula was performed in both eyes before glaucoma surgery and 3 months postoperatively
- The FAZ area is decreased with IOP-lowering surgery in patients with POAG, and change in the FAZ area was significantly correlated with both preoperative foveal sensitivity and change in IOP.

Shoji T, Kanno J, Weinreb RN, Yoshikawa Y, Mine J, Ishii H, Ibuki H, Shinoda K. OCT angiography measured changes in the foveal avascular zone area after glaucoma surgery. *British Journal of Ophthalmology.* 2022 Jan 1;106(1):80-6.


51



52

Structure	AMD Photos/OCT
Function	?
Early Diagnosis	Dark Adaptation/OCT-A (wet)

53



54

### Recent Systematic Literature Review

- This systematic review indicates **overwhelming** evidence of reasonable quality for an association between impaired DA and AMD
- Data on the repeatability and reproducibility of DA measurement are sparse
- Higgins BE, Taylor DJ, Binns AM, Crabb DP. Are current methods of measuring dark adaptation effective in detecting the onset and progression of age-related macular degeneration? A systematic literature review. *Ophthalmology and therapy*. 2021 Feb 9:1-8.

55

### OCT-A shows SRNV in AMD

- Can differentiate between SRNV type 1 and 2
  - Type 1
    - New vessels located **BELOW RPE** and **ABOVE** Bruch's membrane
  - Type 2
    - New vessels located **ABOVE the RPE** and **ABOVE** Bruch's membrane

Ma J, Desai R, Neuper P, Gill M, Fawzi A, Skarinda D. Optical coherence tomographic angiography imaging in age-related macular degeneration. *Ophthalmology and eye diseases*. 2017 Feb 22:9:117917213668075.

56

### Billing/Coding

Description	CPT Code	Average Medicare Reimbursement
ERG with interpretation and report	92273	\$133
Dark adaptation with interpretation and report	92284	\$61
OCT with interpretation and report	92134	\$41

57

### Case

- 53 Y/O W/M
- Type 1 Diabetes x 20 years, Hypercholesterolemia x 3 years
- Mild non-proliferative diabetic retinopathy x 5 years
- Last HA1C 6.9
- BCVA 20/20 OD and OS


58

### Optomaps


59

### Angio Retina QuickVue


60




61



62



63




64

### Case

- 92 Y/O W/F
- Type 2 Diabetes x 15 years
- Last HbA1c 7.3
- Entering Va 20/30 and 20/50 ph to 20/25 and 20/30
- Previous cataract surgery
- Moderate NPDR OU

65




66





67




68

### Treatment

- Began fish oil supplement
- Increased exercise
- Increased Metformin

69



70

### Dr Score

- Improved from 24.1 to 22.8

Device and Test Information	
Serial Number (S001481)	Manufacturer: IGC Technologies, Inc.
Test protocol: DR Assessment	Firmware version: 2.1.0 Reference date: 2022-01-06/154
Electrodes: Sensor Strips	Electrodes: Sensor Strips

DR Score	
Operator-adjusted level	24.1
DR score	24.1
90% Reference Interval	<20.0
95% Reference Interval	<18.0

Probability of DME: >100%


  

Device and Test Information	
Serial Number (S001481)	Manufacturer: IGC Technologies, Inc.
Test protocol: DR Assessment	Firmware version: 2.1.0 Reference date: 2022-01-06/154
Electrodes: Sensor Strips	Electrodes: Sensor Strips

DR Score	
Operator-adjusted level	22.8
DR score	22.8
90% Reference Interval	<20.0
95% Reference Interval	<18.0

Probability of DME: >100%

71



72





Case

- 80 Y/O W/F
- Dx with AMD 2013
- Used AREDS/AREDS2 "off and on"
- 6 months ago Adapt Dx Rod Intercept 13.2

73

## Optomaps


74

And now...


- 6 months ago, began new supplement, reports excellent compliance
- Adapt Dx 12.1 (Baseline 13.2)

75

Cross Line Comparison Report










76



77

### Three Ocular Disease States

	Glaucoma	Diabetic Retinopathy	AMD
Structure	Photos/OCT 	Photos/OCT 	Photos/OCT 
Function	Visual Fields 	?	?
Early Diagnosis	ERG/OCT-A 	ERG/OCT-A 	Dark Adaptation/OCT-A (wet) 

78